This Amendment No. 2 to the Tender Offer Statement on Schedule TO (this
Amendment) amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on October 13, 2023 (as it may be further amended and supplemented from time to time, the Schedule
TO) and relates to the offer by Yosemite Falls Acquisition Corporation, a Delaware corporation and a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation (Lilly), to purchase all of the issued and outstanding
shares of common stock, par value $0.0001 per share (the Shares), of POINT Biopharma Global Inc., a Delaware corporation (POINT), at a purchase price of $12.50 per Share, net to the stockholder in cash, without interest and
less any applicable tax withholding, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 13, 2023, and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be
amended or supplemented from time to time, collectively constitute the Offer), copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by
reference to the extent relevant to the items in this Amendment. Capitalized terms used but not defined herein have the respective meanings ascribed to them in the Schedule TO.
Items 1 through 9 and Item 11.
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented by adding a new paragraph at the
end of Section 15 Conditions of the Offer of the Offer to Purchase to read as follows:
Antitrust Condition has been satisfied by the expiration of the HSR Act waiting period, effective November 7, 2023 at 11:59 p.m., Eastern time.
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented by adding the following
sentence at the end of the second paragraph under the subheading Antitrust Compliance in Section 16 Certain Legal Matters; Regulatory Approvals of the Offer to Purchase:
Lilly and POINT filed their respective Premerger Notification and Report Forms pursuant to the HSR Act with the FTC and the Antitrust
Division on October 23, 2023 initiating a 15-day waiting period. The 15-day waiting period under the HSR Act expired on
November 7, 2023 at 11:59 p.m., Eastern Time. Accordingly, the Antitrust Condition has been satisfied. The Offer continues to be subject to the remaining conditions set forth in this Offer to Purchase. See Section 15
Conditions of the Offer.
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and
supplemented by deleting the last paragraph under the subheading Certain Litigation in Section 16 Certain Legal Matters; Regulatory Approvals of the Offer to Purchase and replacing it with the following paragraph:
POINT has also received certain demand letters from purported stockholders of POINT making similar assertions as the foregoing
complaints. In addition, POINT has received a letter from a purported stockholder seeking, pursuant to Delaware law, to inspect POINTs books and records in connection with the Transactions. The outcome of the matters described above
cannot be predicted with certainty. Additional lawsuits may be filed against POINT, the POINT Board, Lilly and/or Purchaser in connection with the Merger Agreement, the Transactions, the Schedule TO and the
Schedule 14D-9. If additional similar complaints are filed, absent new or different allegations that are material, Lilly, Purchaser and/or POINT will not necessarily announce such additional
The Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented as
On November 8, 2023 in order for the parties to satisfy outstanding closing conditions, Lilly announced an extension
of the Expiration Time until 5:00 p.m., Eastern Time, on November 16, 2023, unless the Offer is further extended or earlier terminated. The Offer was previously scheduled to expire at one minute past 11:59 p.m., Eastern Time, on
November 9, 2023. In case the Offer is extended again, a public announcement of such extension will be made no later than 9:00 a.m., Eastern Time, on the business day after the previously scheduled Expiration Time. The procedures regarding the
extension of the Expiration Time are described in Section 1 Terms of the Offer of the Offer to Purchase.